Recurrence-free survival was numerically higher with adjuvant pembrolizumab, but difference was ...
Median duration of recurrence-free survival was 61.1 months with nivolumab and ...
Greatest effect was seen when nicotinamide was initiated after the first ...
Suggestive increases for prostate and colorectal cancer mortality observed with more ...
PanDerm was evaluated on a wide range of clinical tasks and ...
Leveraging whole slide embeddings from pretrained machine learning models can improve ...
ctDNA detection at baseline was associated with worse recurrence-free, overall survival ...